Clinical evaluation of VIMANG® in the treatment of oral homogenous leucoplakia
Abstract
Introduction: oral leukoplakia is the most frequent premalignant lesion in the world; in the province of Ciego de Ávila, more than 100 cases are diagnosed annually. Among the natural antioxidant products that can stop the evolutionary process of cancer is the VIMANG®, made from the bark of Mangifera indica L, with proven antioxidant effects in vivo and in vitroalthough its therapeutic use is poorly treated in the medical literature.Objective: to evaluate the use of VIMANG® in the treatment of homogeneous oral leukoplakia.
Method: a monocentric study of therapeutic extension was carried out at the Maxillofacial Surgery Service of the Provincial General Teaching Hospital "Dr. Antonio Luaces Iraola" in Ciego de Ávila from January to December 2014; the sample consisted of 60 patients diagnosed with homogeneous oral leukoplakia, which were distributed in an experimental group (treated with VIMANG®) and a control group (treated with vitamins). The responses to treatment were evaluated in the initial, intermediate and final phases, as well as adverse reactions and patient compliance.
Results: the majority of patients in both groups had risk factors for the disease (smoking, alcoholism, clear skin and residents in urban areas); lesions on the lips were the most frequent. Regardless of these factors, 76,7 % of the patients in the experimental group and 63,3 % of the control group evolved favorably.
Conclusions: VIMANG® was more effective in treating homogeneous oral leukoplakia than conventional therapy.Downloads
Published
How to Cite
Issue
Section
License
MediCiego does not apply publication charges. The journal is available in open access without restrictions, in compliance with the international policy on open access to information for the exchange of global knowledge.
The authors will retain their copyright and guarantee the journal the right of first publication of their work. MediCiego is licensed under the Creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/deed.es_ES), so it is allowed to copy, reproduce, distribute, publicly communicate the work and generate derivative works, as long as the original author is cited and acknowledged. However, it is not allowed to use the original work for commercial or lucrative purposes.
Authors must sign a copyright agreement through an affidavit of authorship and originality, before publishing.
The authors authorize the publication of their writings; they retain the copyright, and assign to the journal all the rights protected by the Copyright Law that governs Cuba, and implies the edition to disseminate the work.
Likewise, they may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with the recognition of having been first published in this journal.
Declaration of authorship: download here the Affidavit